key: cord-0771042-5fnvsvm9
authors: Lamb, Christopher A.; Sebastian, Shaji; Kent, Alexandra J.; Segal, Jonathan P.; Gonzalez, Haidee A.; Brookes, Matthew J.; Mehta, Shameer J.; Subramanian, Sreedhar; Bhala, Neeraj; Hicks, Lucy C.; Conley, Thomas E.; Patel, Kamal V.; Walker, Gareth J.; Kennedy, Nicholas A.
title: Letter: risk of severe COVID‐19 outcomes associated with inflammatory bowel disease medications—reassuring insights from the United Kingdom PREPARE‐IBD multicentre cohort study
date: 2021-05-07
journal: Aliment Pharmacol Ther
DOI: 10.1111/apt.16349
sha: ea270b037d61d0001426584702163f1e5c5414ab
doc_id: 771042
cord_uid: 5fnvsvm9

LINKED CONTENT This article is linked to Taxonera et al paper. To view this article, visit https://doi.org/10.1111/apt.15804

Letter: risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications-reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study EDITORS, We read with interest the study by Taxonera et al, describing clinical characteristics and mortality associated with COVID-19 in a Spanish inflammatory bowel disease (IBD) cohort. 1 During the early COVID-19 pandemic, the British Society of Gastroenterology (BSG) developed a risk stratification grid to inform the United Kingdom (UK) government regarding strict social isolation, termed 'shielding'. 2 IBD patients thought to be most clinically vulnerable to SARS-CoV-2 included recent commencement of combination biologic and immunomodulator therapy, prednisolone ≥20 mg/day, comorbidities, age ≥70 years or clinically active disease in those receiving immunosuppression. Mesalazine was not considered to increase risk. An acknowledged limitation was an absence of COVID-19 risk data, with extrapolation from historical cohort studies reporting opportunistic infections. [3] [4] [5] We sought to identify patient or IBD medication-related factors associated with severe outcomes from COVID-19 in the UK. with SECURE-IBD, univariable analysis identified biologics as protective (P = 0.031). In contrast to SECURE-IBD data, univariable analysis showed a protective association with thiopurines (P = 0.041). However, on multivariable analysis, no association of severe COVID-19 outcomes with thiopurine or biologic exposure was seen.

Our data provide reassurance for continued evidence-based use of corticosteroids, immunomodulators and biologics in IBD during the ongoing COVID-19 pandemic, and is consistent with an as yet unexplained association between mesalazine use and severe COVID-19 outcomes.

We are grateful to the clinical and research teams in the participating sites for identification of patients, data collection and data entry. UK gastroenterology trainees and trainee networks (MaGNET: Mersey Note: n = 208 complete data for multivariable analysis.

Three patients were excluded from multivariable analysis as lacked complete data across all variables.

Abbreviations: BMI, body mass index, BSG, British Society of Gastroenterology, CD, Crohn's disease, COVID-19, Coronavirus disease 2019, HBI, Harvey-Bradshaw Index, IQR, interquartile range, UC, ulcerative colitis, IBD-U, inflammatory bowel disease unclassified, PGA, physicians' global assessment.

*P value from univariable logistic regression.; **P value from multivariable logistic regression.

Neeraj Bhala

2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases

British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic

Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry

Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines

Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases

but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry

Effect of IBD medications on COVID-19 outcomes: results from an international registry

Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study

Baseline disease activity and steroid therapy stratify risk of COVID-19 in patients with inflammatory bowel disease